keyword
MENU ▼
Read by QxMD icon Read
search

Carcinoma cells renal

keyword
https://www.readbyqxmd.com/read/28549248/metastatic-chromophobe-renal-cell-carcinoma-treated-with-targeted-therapies-a-renal-cross-channel-group%C3%A2-study
#1
Emeline Colomba, Gwénaël Le Teuff, Tim Eisen, Grant D Stewart, Kate Fife, James Larkin, Andrea Biondo, Lisa Pickering, Anandagopal Srinivasan, Helen Boyle, Lisa Derosa, Cora N Sternberg, Federica Recine, Christy Ralph, Carolina Saldana, Philippe Barthélémy, Jean Christophe Bernhard, Howard Gurney, Gregory Verhoest, Elodie Vauleon, Pierre Bigot, Julien Berger, Christian Pfister, Gwenaelle Gravis, Jean-Michel Rodier, Stéphane Culine, Armelle Caty, Frederic Rolland, Franck Priou, Bernard Escudier, Laurence Albiges
BACKGROUND: Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. METHODS: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era...
May 23, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28549228/is-cabozantinib-really-better-than-sunitinib-as-first-line-treatment-of-metastatic-renal-cell-carcinoma
#2
Sebastiano Buti, Melissa Bersanelli
No abstract text is available yet for this article.
June 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28549227/too-much-or-just-enough-of-a-good-thing-vascular-endothelial-growth-factor-inhibition-in-renal-cell-carcinoma
#3
Lauren C Harshman
No abstract text is available yet for this article.
June 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28548948/effect-of-renal-embolization-in-patients-with-synchronous-metastatic-renal-cell-carcinoma-a-retrospective-comparison-of-cytoreductive-nephrectomy-and-systemic-medical-therapy
#4
Sung Han Kim, Jung Kwon Kim, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
OBJECTIVE: To compare survival outcomes for renal embolization (RE) to cytoreductive nephrectomy (CN) and no primary renal treatment (NT) among patients with synchronous metastatic renal cell carcinoma (mRCC) treated using either targeted therapy (TT) or immunotherapy (IT). RESULTS: The median follow-up duration was 81.3 months, with a duration of first-line treatment of 3.5 months. Among the 211 patients, the median PFS and OS were 4.4 and 10.6 months. Specifically for patients receiving TT (124 patients), the PFS and OS were 5...
May 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28548943/intra-tumour-molecular-heterogeneity-of-clear-cell-renal-cell-carcinoma-reveals-the-diversity-of-the-response-to-targeted-therapies-using-patient-derived-xenograft-models
#5
Baoan Hong, Yong Yang, Sheng Guo, Shayiremu Duoerkun, Xiaohu Deng, Dawei Chen, Shijun Yu, Wubin Qian, Qixiang Li, Qing Li, Kan Gong, Ning Zhang
Inter- and intra-tumour molecular heterogeneity is increasingly recognized in clear cell renal cell carcinoma (ccRCC). It may partially explain the diversity of responses to targeted therapies and the various clinical outcomes. In this study, a 56-year-old male ccRCC patient with multiple metastases received radical nephrectomy and resection of the metastatic tumour in chest wall. The surgical specimens were implanted into nude mice to establish patient-derived xenograft (PDX) models with KI2367 model derived from the primary tumour and KI2368 model from the metastastic tumour...
May 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28547985/renal-cell-carcinoma-metastasizing-to-pancreatic-neuroendocrine-neoplasm-the-second-case-described-in-the-world-literature
#6
Katarzyna Bednarek-Rajewska, Przemysław Zalewski, Danuta Bręborowicz, Aldona Woźniak
Tumor-to-tumor metastases are very rare events. We report a case of a 64-year-old man who presented with a tumor of the pancreas. The patient underwent partial pancreatectomy. Frozen section diagnosis of the tumor was an endocrine neoplasm. Paraffin block slide examination revealed a tumor consisting of two components: pancreatic endocrine neoplasm at the periphery of the tumor and the central part composed of clear cells with delicate vessels. The results of immunohistochemical stains revealed renal cell carcinoma surrounded by pancreatic endocrine neoplasm, therefore representing an unusual case of renal cell carcinoma metastasizing to a pancreatic endocrine neoplasm...
2017: Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists
https://www.readbyqxmd.com/read/28547982/clinicopathological-study-of-5-cases-of-renal-cell-carcinoma-with-t-6-11-p21-q12
#7
Naoto Kuroda, Kenji Yorita, Naomi Sasaki, Akira Ishihara, Keiko Matsuura, Tsutomu Daa, Shintaro Mori, Aya Sasaki, Shuji Mikami, Kazuto Shigematsu, Yoji Nagashima
Renal cell carcinoma (RCC) with t(6;11)(p21;q12) has been incorporated into the recent WHO classification. We performed a clinicopathological study of 5 cases with such a tumor. The patients consisted of 4 males and 1 female. The age of patients ranged from 17 to 57 years with a mean age of 38.6 years. Tumor sizes ranged from 2.8 to 11 cm with a mean value of 6.5 cm. Despite immunotherapy and molecular-targeted therapy, one patient died of the disease 28 months after the surgery. Grossly, the cut surface of this tumor showed grayish white color in at least the focal area of all tumors...
2017: Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists
https://www.readbyqxmd.com/read/28546711/management-of-ivc-thrombus-surgical-strategies-and-outcomes
#8
REVIEW
Amlesh Seth
Renal cell carcinoma is the most lethal among all urological cancers. The lethality increases with advancing stages of the disease. Renal tumors show a peculiar propensity to invade the venous system. Such invasion not only worsens the disease prognosis but also increases the surgical morbidity making treatment of such tumors challenging. Several small volume series have been published regarding management and outcomes of renal tumors with inferior vena cava (IVC) thrombus which show encouraging results when addressed properly...
June 2017: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28546710/current-status-of-nephron-sparing-surgery-nss-in-the-management-of-renal-tumours
#9
REVIEW
Vivek Venkatramani, Sanjaya Swain, Ramgopal Satyanarayana, Dipen J Parekh
Nephron-sparing surgery has emerged as the surgical treatment of choice for small renal masses over the past two decades, replacing the traditional teaching of radical nephrectomy for renal cell carcinoma. With time, there has been an evolution in the techniques and indications for partial nephrectomy. This review summarizes the current status of nephron-sparing surgery for renal carcinoma and also deals with the future of this procedure.
June 2017: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28546709/salvage-surgery-for-cervical-cancer-recurrences
#10
P Rema, Arun Peter Mathew, S Suchetha, Iqbal Ahmed
Cervical cancer usually presents in advanced stages and is treated with chemoradiation. About 15-20 % patients present with local recurrence after chemoradiation. Radical surgical resection is the only treatment modality offering long term survival benefit in recurrent cervical cancer. The most common surgical option for these patients is pelvic exenteration. Radical hysterectomy may be done for patients with a small centrally located recurrence in the cervix with no infiltration of adjacent structures. The aim of this study was to evaluate the morbidity and survival outcome following radical hysterectomy and pelvic exenteration for recurrent cancer cervix...
June 2017: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28546525/pazopanib-for-the-treatment-of-non-clear-cell-renal-cell-carcinoma-a-single-arm-open-label-multicenter-phase-ii-study
#11
Ki Sun Jung, Su Jin Lee, Se Hoon Park, Jae-Lyun Lee, Se-Hoon Lee, Jae Yun Lim, Jung Hun Kang, Suee Lee, Sun Young Rha, Kyung Hee Lee, Ho Young Kim, Ho Yeong Lim
Purpose: The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not been analyzed. We therefore designed a single-arm, open-label, phase II study to determine the efficacy and safety of pazopanib in patients with nccRCC. Materials and Methods: Patients with locally advanced or metastatic nccRCC, except for collecting duct or sarcomatoid type, received 800mg/day of pazopanib daily until progression of disease or intolerable toxicity...
May 22, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28546463/a-phase-ii-study-of-everolimus-plus-oral-prednisone-in-patients-with-metastatic-renal-cell-cancer
#12
Cristian Lolli, Valentina Gallà, Giuseppe Schepisi, Domenico Barone, Salvatore Luca Burgio, Antonio Maugeri, Bernadette Vertogen, Dino Amadori, Ugo De Giorgi
LESSONS LEARNED: The combination of everolimus and low-dose prednisone administered daily was hypothesized to prevent noninfectious pneumonitis (NIP) and mucositis, two common adverse events related to everolimus. Although mucositis was detected in only one case, all-grade NIP occurred in four of eight cases (50%), and this was considered enough to stop accrual of the study.These data suggest the need for careful monitoring of patients receiving everolimus who are treated with corticosteroids...
May 25, 2017: Oncologist
https://www.readbyqxmd.com/read/28546287/immune-atlases-created-for-kidney-lung-cancers
#13
(no author information available yet)
Two groups of researchers have generated the first comprehensive "immune atlases" of clear cell renal cell carcinoma and early lung adenocarcinoma. Their work better illuminates the tumor immune microenvironment and may lead to more effective immunotherapy strategies.
May 25, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28545998/a-randomized-phase-ii-study-to-determine-the-effect-of-2-different-doses-of-aflibercept-in-patients-with-metastatic-renal-cell-carcinoma-ecog-acrin-e4805
#14
Roberto Pili, Opeyemi Jegede, Michael A Carducci, Judith Manola, David L Groteluschen, Leonard L Appleman, Glenn Liu, James C Shanks, Shaker R Dakhil, Janice Dutcher, Robert S DiPaola
BACKGROUND: Aflibercept is a recombinantly produced fusion protein that has potent anti-vascular endothelial growth factor (VEGF) activity. We tested whether aflibercept has clinical activity in clear-cell renal cell carcinoma (ccRCC). The recommended phase II dose was 4 mg/kg but several patients (pts) treated at 1 mg/kg showed prolonged progression-free survival. We therefore tested both doses in a parallel group randomized trial. PATIENTS AND METHODS: Eligible pts had histologically confirmed advanced or metastatic ccRCC and previous treatments included exposure to a VEGF receptor tyrosine kinase inhibitor...
April 26, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28545682/percutaneous-microwave-ablation-of-renal-cancers-under-ct-guidance-safety-and-efficacy-with-a-2-year-follow-up
#15
P Chan, S Vélasco, G Vesselle, S Boucebci, G Herpe, B Debaene, P Ingrand, J Irani, J-P Tasu
AIM: To evaluate the safety and efficiency of percutaneous microwave ablation (MWA) of renal cell carcinomas (RCC) carried out under computed tomography (CT) guidance. MATERIALS AND METHODS: A retrospective study was performed on RCC that was either histologically proven or diagnosed at imaging (Bosniak IV cyst) and treated by MWA under general anaesthesia with CT guidance. Indications for percutaneous ablation were based on the American Urological Association recommendations...
May 22, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28545581/increased-serum-level-of-soluble-interleukin-2-receptor-is-associated-with-a-worse-response-of-metastatic-clear-cell-renal-cell-carcinoma-to-interferon-alpha-and-sequential-vegf-targeting-therapy
#16
Akinori Nukui, Akinori Masuda, Hideyuki Abe, Kyoko Arai, Ken-Ichiro Yoshida, Takao Kamai
BACKGROUND: Renal cell carcinoma (RCC) is a tumor with immunogenic properties. Soluble interleukin-2 receptor (sIL-2R) has a role in T cell activation and may be important for immune regulation in various conditions, including infections, transplantation rejection, autoimmune inflammatory states, and cancer. We investigated the prognostic value of the serum sIL-2R level in patients with metastatic RCC receiving IFN-alpha and vascular endothelial growth factor (VEGF)-targeting therapy...
May 25, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28545466/preoperative-cholesterol-level-as-a-new-independent-predictive-factor-of-survival-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-cyto-reductive-nephrectomy
#17
Hakmin Lee, Yong June Kim, Eu Chang Hwang, Seok Ho Kang, Sung-Hoo Hong, Jinsoo Chung, Tae Gyun Kwon, Cheol Kwak, Hyeon Hoe Kim, Jong Jin Oh, Sang Chul Lee, Sung Kyu Hong, Sang Eun Lee, Seok-Soo Byun
BACKGROUND: The obesity and lipid metabolism were previously proposed to be related with the clinical outcomes of metastatic renal cell carcinoma (mRCC). We tried to investigate the relationship between preoperative cholesterol level (PCL) and survival outcomes in patients with mRCC. METHODS: We analysed the data of 244 patients initially treated with cyto-reductive nephrectomy after being diagnosed with mRCC. Patients were stratified into two groups according to the PCL cut-off level of 170 mg/dL...
May 25, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28545465/an-increase-in-long-non-coding-rna-pandar-is-associated-with-poor-prognosis-in-clear-cell-renal-cell-carcinoma
#18
Yi Xu, Yanyue Tong, Jianyong Zhu, Zhangming Lei, Lijun Wan, Xiuwen Zhu, Feng Ye, Liping Xie
BACKGROUND: Nearly 30% of clear cell renal cell carcinoma (ccRCC) patients present with metastasis at the time of diagnosis, and the prognosis for these patients is poor. Therefore, novel potential prognostic biomarkers and therapeutic targets for ccRCC could be helpful. Emerging evidence indicates that lncRNAs play important roles in cancer tumorigenesis and could be used as potential biomarkers or therapeutic targets. PANDAR (promoter of CDKN1A antisense DNA damage activated RNA) is a relatively novel lncRNA that plays an important role in the development of multiple cancers...
May 25, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28545036/the-long-non-coding-rna-neat1-enhances-epithelial-to-mesenchymal-transition-and-chemoresistance-via-the-mir-34a-c-met-axis-in-renal-cell-carcinoma
#19
Fei Liu, Na Chen, Yanchun Gong, Ruihai Xiao, Weichao Wang, Zhengyue Pan
Long non-coding RNAs (lncRNAs) have emerged as new gene regulators and prognostic markers in various cancers. Although the lncRNA nuclear enriched abundant transcript 1 (NEAT1) has been associated with tumorigenesis, its functions in renal cell carcinoma (RCC) have not been elucidated. We determined that NEAT1 is up-regulated in RCC tissue compared to corresponding non-tumor tissue. High NEAT1 expression was associated with tumor progression and poor survival in RCC patients. NEAT1 knockdown suppressed RCC cell proliferation by inhibiting cell cycle progression, and inhibited RCC cell migration and invasion by reversing the epithelial-to- mesenchymal transition phenotype...
May 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28544682/hypertension-induced-by-tyrosine-kinase-inhibitors-for-the-treatment-of-renal-cell-carcinoma-in-hemodialysis-patients-a-single-center-experience-and-review-of-the-literature
#20
Kentaro Nakai, Hideki Fujii, Keiji Kono, Shunsuke Goto, Shinichi Nishi
Malignancy is a major cause of mortality in dialysis patients. Although molecular-targeted anticancer drugs, including tyrosine-kinase inhibitors, are used for advanced renal cell carcinoma treatment, there are few reports on their effectiveness and safety in dialysis patients. Renal cell carcinoma dialysis patients treated at our hospital from 2010 to 2013 participated in this study. Thirteen patients were treated with tyrosine-kinase inhibitors and 15 patients with surgery only (control group). During treatment, blood pressure changes and dry weight reduction tended to be greater in the tyrosine-kinase inhibitor group than in controls...
May 23, 2017: Therapeutic Apheresis and Dialysis
keyword
keyword
116101
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"